ERMS tumor also harbored additional gene alterations: low amplification of EGFR, PDGFRA, and CDK4 genes, and loss of heterozygosity of CDKN2A and 19q12-19q13.43 chromosomal regions. The gene discussed is EGFR; the disease is neoplasm.